Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

BACKGROUND: Panobinostat is a new agent for the treatment of relapsed and refractory multiple myeloma (rrMM) as part of a combination regimen. This article presents an overview of the mechanism of action, pharmacokinetics, safety, efficacy, patient care strategies, and role of the agent in treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Redic, Kimberly A, Hough, Shannon M, Price, Erika M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869663/
https://www.ncbi.nlm.nih.gov/pubmed/27274274
http://dx.doi.org/10.2147/OTT.S87962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869663/
https://www.ncbi.nlm.nih.gov/pubmed/27274274
http://dx.doi.org/10.2147/OTT.S87962

Ejemplares similares